Chimerix, Inc. (NASDAQ:CMRX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET

Company Participants

Mike Sherman – President & Chief Executive Officer

Michael Andriole – Chief Financial & Business Officer

Allen Melemed – Chief Medical Officer

Joshua Allen – Chief Technology Officer, Imipridones

Michelle Laspaluto – Vice President, Strategic Planning & Investor Relations

Conference Call Participants

Maury Raycroft – Jefferies

Edward White – H.C. Wainwright & Co.

Naureen Quibria – Maxim Group

Soumit Roy – Jones Trading

David Nierengarten – Wedbush Securities

Troy Langford – Cowen Inc.

Operator

Good morning, ladies, and gentlemen, and welcome to the Chimerix First Quarter 2022 Earnings Conference Call. I would now like to introduce to your host for today's call Michelle Laspaluto, Vice President of Strategic Planning, and Investor Relations at Chimerix. Please proceed.

Michelle Laspaluto

Thank you. Good morning, everyone and welcome to the Chimerix first-quarter 2022, financial and operating results conference call. This morning, we issued two press releases when to announce the sale of TEMBEXA to Emergent Bio Solutions, and one announcing our first-quarter operating operations. You can access these press releases in our Investors section of the website. With me on today's call are President and Chief Executive Officer Mike Sherman, Chief Financial Officer, Allen Melemed, Chief Financial and Business Officer, Mike Andriole and our Chief and [Indiscernible] Technology Officer, Josh Allen.

Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. These risks and uncertainties, and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for more complete disclosure of these risks and uncertainties. At this time, I would like to turn the call over to our President and Chief Executive Officer, Mike Sherman.

Mike Sherman

Thanks, Michelle. Good morning, everyone. Thanks for joining us. We've had an active couple of months. So, let me get right to the updates and I'll start with TEMBEXA. This program has been central to our strategy for a couple of reasons. First, we're fulfilling an important need to protect the population from the possibility of a smallpox outbreak. And we've done that with the first treatment approved for all ages and one that's likely robust even in the face of the inevitable mutations that compromise the efficacy of other treatments.